Kuros Biosciences (XSWX:KURN) Change In Receivables : CHF-4.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Change In Receivables?

Kuros Biosciences's change in receivables for the quarter that ended in Dec. 2023 was CHF-2.90 Mil. It means Kuros Biosciences's Accounts Receivable increased by CHF2.90 Mil from Jun. 2023 to Dec. 2023 .

Kuros Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was CHF-4.57 Mil. It means Kuros Biosciences's Accounts Receivable increased by CHF4.57 Mil from Dec. 2022 to Dec. 2023 .

Kuros Biosciences's Accounts Receivable for the quarter that ended in Dec. 2023 was CHF6.41 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Kuros Biosciences's Days Sales Outstanding for the six months ended in Dec. 2023 was 56.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kuros Biosciences's liquidation value for the six months ended in Dec. 2023 was CHF6.35 Mil.

Kuros Biosciences Change In Receivables Historical Data

The historical data trend for Kuros Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Change In Receivables Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.48

-0.38

-0.74

-1.64

-4.57

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-0.07	-5.73	4.09	-1.67	-2.90

Kuros Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-4.57 Mil.

Kuros Biosciences (XSWX:KURN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kuros Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.411	/	20.698	*	91
=	56.53

2. In Ben Graham's calculation of liquidation value, Kuros Biosciences's accounts receivable are only considered to be worth 75% of book value:

Kuros Biosciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	13.866	-	14.752	+	0.75 * 6.411	+	0.5 * 4.856
=	6.35

Kuros Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines